UBS AM
BMY.RT

UBS AM’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

UBS AM’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20,768
Closed -$14.3K – 2633
2020
Q4 		$14.3K Sell
20,768
-33,799
-62% -$72K ﹤0.01% 2546
2020
Q3 		$123K Hold
54,567
– – ﹤0.01% 2452
2020
Q2 		$195K Sell
54,567
-57,462
-51% -$207K ﹤0.01% 2392
2020
Q1 		$426K Buy
112,029
+20,768
+23% +$68.4K ﹤0.01% 2033
2019
Q4 		$275K Buy
+91,261
New +$237K ﹤0.01% 2388

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

UBS AM's BMY.RT Position: Q1 2021 in Review

UBS AM sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 20,768 shares — an estimated $14.3K sold.

UBS AM first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $426K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • UBS AM reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • UBS AM sold 20,768 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14.3K.
  • UBS AM first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • UBS AM's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $426K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on UBS AM's 13F filing for Q1 2021, filed 14 May 2021.